Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Navidea Biopharmaceuticals (NAVB +1.9%) gains after Burrill Institutional Research initiated the...

  • Tuesday, January 22, 12:32 PM ET
    Navidea Biopharmaceuticals (NAVB +1.9%) gains after Burrill Institutional Research initiated the shares with a Market Outperform on valuation and a price target of $5 a share. The firm says the stock represents an undervalued opportunity with multiple near-term drivers that are likely to create shareholder value in 2013. Separately, Aegis Capital starts the stock with a Hold rating and a $3.00 price target.
Track new comments on this story

This news story has 1 comment:

  •  
    lets go......stop 6,5 ??
    22 Jan, 02:34 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »